Unknown PHASE2 INTERVENTIONAL NCT00319865

PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma

Sponsor: Celgene Corporation

Conditions Multiple Myeloma

Interventions Adriamycin Dexamethasone Thalidomide Velcade

Updated 5 times since 2017 Last updated: Apr 28, 2006 Started: Nov 30, 2005 Completion: Sep 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00319865, this PHASE2 trial focuses on Multiple Myeloma and remains ongoing. Sponsored by Celgene Corporation, it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE2

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
Korean Multiple Myeloma Working Party

Data source: Korean Multiple Myeloma Working Party

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Inchon, South Korea